408 related articles for article (PubMed ID: 23824496)
1. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
2. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
3. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department.
Lynn JJ; Chen KF; Weng YM; Chiu TF
Hematol Oncol; 2013 Dec; 31(4):189-96. PubMed ID: 23303687
[TBL] [Abstract][Full Text] [Related]
4. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
5. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
Orme LM; Babl FE; Barnes C; Barnett P; Donath S; Ashley DM
Pediatr Blood Cancer; 2014 Aug; 61(8):1427-33. PubMed ID: 24604835
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.
Li X; Luthra R; Morrow PK; Fisher MD; Reiner M; Barron RL; Langeberg WJ
J Oncol Pharm Pract; 2016 Oct; 22(5):679-89. PubMed ID: 26378158
[TBL] [Abstract][Full Text] [Related]
7. Retrospective review of gynecologic oncology patients with therapy-induced neutropenic fever.
McMeekin DS; Gazzaniga C; Berman M; DiSaia P; Manetta A
Gynecol Oncol; 1996 Aug; 62(2):247-53. PubMed ID: 8751557
[TBL] [Abstract][Full Text] [Related]
8. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy.
Moreira-Pinto J; Leão I; Palmela C; Branco F; Godinho J; Simões P; Leal-Costa L; Lopes F; Faria A; Casa-Nova M; Escária A; Costa F; Galvão I; Teixeira J; Passos-Coelho JL
Oncol Res Treat; 2020; 43(11):605-612. PubMed ID: 32818937
[TBL] [Abstract][Full Text] [Related]
9. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
10. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
[TBL] [Abstract][Full Text] [Related]
11. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer.
Quezada G; Sunderland T; Chan KW; Rolston K; Mullen CA
Pediatr Blood Cancer; 2007 Mar; 48(3):273-7. PubMed ID: 16435377
[TBL] [Abstract][Full Text] [Related]
12. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
13. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
14. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
Moon H; Choi YJ; Sim SH
PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].
Masmoudi S; Khanfir A; Maalej-Mezghan S; Hammami A; Frikha M
Tunis Med; 2015 Apr; 93(4):217-22. PubMed ID: 26375737
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
[TBL] [Abstract][Full Text] [Related]
17. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
18. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
Raisch DW; Holdsworth MT; Winter SS; Hutter JJ; Graham ML
Value Health; 2003; 6(2):158-66. PubMed ID: 12641866
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010).
Britton BM; Kelleher ME; Gregor TP; Sorenmo KU
Vet Comp Oncol; 2014 Dec; 12(4):266-76. PubMed ID: 22998454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
